RE: McLaughlin Joins Avacta3 Sep 2021 17:03
McLaughlin is a highly experienced oncology drug developer, bringing over 25 years’ experience in research and translational drug development in the pharmaceutical and biotech sectors, having led teams from early research through to clinical development.
She started her career at GlaxoSmithKline and has subsequently held leadership positions in multiple biotech companies including vice president, translational research at Antisoma plc and director of pre-clinical development at BTG plc (now part of Boston Scientific).
Previously in the position of Head of Translational Science she now become Chief Scientific Officer. Excellent track record and experience to fit the role.